Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats

Diabetes/Metabolism Research and Reviews

Volumn 28, Issue 2, 2012, Pages 132-138

  de la Cruz, J P ^a   Jebrouni, N ^a   Lopez Villodres J A ^a   Munoz Marin J ^a   Guerrero, A ^a   Gonzalez Correa J A ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Diabetic retinopathy; Endothelial dysfunction; Platelets; Terutroban

Indexed keywords

3 NITROTYROSINE; ACETYLSALICYLIC ACID; INSULIN DETEMIR; INTERLEUKIN 6; LIPID PEROXIDE; NITRIC OXIDE; PEROXIDASE; PROSTACYCLIN; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; STREPTOZOCIN; TERUTROBAN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THROMBOXANE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; MALE; NITROSATIVE STRESS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; RETINA BLOOD VESSEL; STREPTOZOCIN DIABETES; THROMBOCYTE AGGREGATION; VASCULARIZATION;

ANIMALS; ASPIRIN; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; EPOPROSTENOL; LIPID PEROXIDATION; MALE; NAPHTHALENES; PLATELET AGGREGATION; PROPIONIC ACIDS; RATS; RATS, WISTAR; RECEPTORS, PROSTAGLANDIN; RETINAL VESSELS; STREPTOZOCIN;

EID: 84857010700     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1283     Document Type: Article

References (33)

1. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15(1): 44-54.
2. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26(7): 2181-2188.
3. De la Cruz JP, Moreno A, Muñoz M, García Campos JM, Sánchez de la Cuesta F. Effect of aspirin plus dipyridamole on the retinal vascular pattern in experimental diabetes mellitus. J Pharmacol Exp Ther 1997; 280(1): 454-459.
4. Reiss AB, Edelman SD. Recent insights into the role of prostanoids in atherosclerotic vascular disease. Curr Vasc Pharmacol 2006; 4(4): 395-408.
5. De La Cruz JP, Moreno A, Guerrero A, Ortega G, González-Correa JA, Sánchez de la Cuesta F. Nitric oxide-cGMP and prostacyclin-cAMP pathways in patients with type II diabetes and different types of retinopathy. Pathophysiol Haemost Thromb 2002; 32(1): 25-32.
6. De La Cruz JP, Moreno A, Guerrero A, Sánchez de la Cuesta F. Antiplatelet effects of prostacyclin and nitric oxide in patients with type I diabetes and ischemic or edematous retinopathy. Platelets 2001; 12(4): 210-217.
7. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109(2): 143-159.
8. De La Cruz JP, Moreno A, Sanchez de la Cuesta F, García Campos J. Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes mellitus. Can J Ophthalmol 1990; 25(7): 329-332.
9. De La Cruz JP, Guerrero A, Paniego MJ, Arranz I, Moreno A, Sánchez De La Cuesta F. Effect of aspirin on prostanoids and nitric oxide production in streptozotocin-diabetic rats with ischemic retinopathy. Naunyn Schmiedebergs Arch Pharmacol 2002; 365(2): 96-101.
10. De La Cruz JP, Moreno A, Mérida F, García Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. Thromb Res 1996; 81(3): 327-337.
11. Moreno A, De La Cruz JP, Mérida F, García Campos J, Sánchez de la Cuesta F. Effects of ditazol on the vascular retinal pattern in experimental diabetes in rats. Haemostasis 1995; 25(4): 166-171.
12. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, García Campos J, Sánchez de la Cuesta F. Effect of camonagrel, a selective thromboxane synthase inhibitor, on retinal vascularization in experimental diabetes. Eur J Pharmacol 1998; 350(1): 81-85.
13. De La Cruz JP, Moreno A, Ruiz-Ruiz MI, Sánchez de la Cuesta F. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. Thromb Res 2000; 97(3): 125-131.
14. De La Cruz JP, Arrebola M, González-Correa JA, Martinez-Cerdán E, Moreno A, Sánchez de la Cuesta F. Effects of clopidogrel and ticlopidine on experimental diabetic ischemic retinopathy in rats. Naunyn Schmiedebergs Arch Pharmacol 2003; 367(2): 204-210.
15. Simonet S, Descombes JJ, Vallez MO, Dubuffet T, Lavielle G, Verbeuren TJ. S18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. Adv Exp Med Biol 1997; 433(1): 173-176.
16. Xu S, Jiang B, Maitland KA, et al. The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. Diabetes 2006; 55(1): 110-119.
17. Gelosa P, Ballerio R, Banfi C, et al. Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. J Pharmacol Exp Ther 2010; 334(1): 199-205.
18. Glassman AB. Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci 1993; 23(1): 47-50.
19. Schror K. Blood vessel wall interactions in diabetes. Diabetes 1997; 46(Suppl 2): 115-118.
20. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3): 257-267.
21. Tesfamariam B, Cohen RA. Role of superoxide anion and endothelium in vasoconstrictor action of prostaglandin endoperoxide. Am J Physiol 1992; 262(6): H1915-H1919.
22. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev 2000; 16(6): 393-407.
23. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130(5): 963-974.
24. Vilahur G, Casaní L, Badimon L. A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. Thromb Haemost 2007; 98(3): 662-669.
25. Hong TT, Huang J, Driscoll E, Lucchesi BR. Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. J Cardiovasc Pharmacol 2006; 48(5): 239-248.
26. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296(5567): 539-541.
27. Viles-Gonzalez JF, Fuster V, Corti R, et al. Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition-a magnetic resonance imaging study. Eur Heart J 2005; 26(15): 1557-1561.
28. Worth NF, Berry CL, Thomas AC, Campbell JH. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005; 183(1): 65-73.
29. Sebeková K, Eifert T, Klassen A, Heidland A, Amann K. Renal effects of S18886 (terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. Diabetes 2007; 56(4): 968-974.
30. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20(7): 1724-1728.
31. Belhassen L, Pelle G, Dubois-Rande JL, Adnot S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J Am Coll Cardiol 2003; 41(7): 1198-1204.
32. Zuccollo A, Shi C, Mastroianni R, et al. The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. Circulation 2005; 112(19): 3001-3008.
33. Shi Y, Feletou M, Ku DD, Man RY, Vanhoutte PM. The calcium ionophore A23187 induces endothelium-dependent contractions in femoral arteries from rats with streptozotocin induced diabetes. Br J Pharmacol 2007; 150(5): 624-632.